Clinical trial
Effect of LY333531 on Vascular and Neural Functions
NCT00482976 · Chromaderm, Inc., Industry · Completed
Key facts
| NCT number | NCT00482976 |
|---|---|
| Title | Effect of LY333531 on Vascular and Neural Functions |
| Official title | The Effects of a Protein Kinase C Beta Inhibitor, LY333531, on Vascular and Neural Functions in Type 2 Diabetes Mellitus - Study B7A-MC-MBDM |
| Lead sponsor | Chromaderm, Inc., Industry |
| Collaborators | Joslin Diabetes Center |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Ruboxistaurin, Placebo |
| Enrollment | 30 |
| Start date | Dec 1, 2003 |
| Completion | Mar 1, 2005 |
| First posted | Jun 6, 2007 |
| Last update posted | Jul 26, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: